Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

- Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3

treatment-experienced patients -

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) in both treatment-naive and treatment-experienced patients chronically-infected with hepatitis C virus (HCV) genotypes 1, 2 and 3. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

The purpose of this 4-week study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy for chronic HCV infection. The previously planned Cohort 3 will continue dose-exploration with administration of R7128 1000mg twice-daily (BID) in treatment-naive patients with HCV genotype 1. Cohort 4 will evaluate R7128 1500mg BID administered in combination with Pegasys plus Copegus in treatment-experienced patients with genotypes 2 or 3 who did not achieve a sustained virologic response (SVR) with previous interferon-based therapy.

There will be 25 patients in each dose cohort with 20 patients randomized to receive R7128 and 5 patients randomized to receive placebo. After completing 4 weeks of the triple combination regimen and a follow-up period of 4 weeks of Pegasys plus Copegus, patients will receive an additional 16 to 40 weeks of open-label dosing of Pegasys plus Copegus under a separate protocol to complete the stand
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research ... Bull of the Day and Panera (Nasdaq: PNRA - Free ... Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - ... and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The biotech ...
(Date:8/22/2014)... , August 22, 2014 ... Hospital TVs Today Lincor announced general availability ... Engagement solution that delivers a range of education, entertainment ...      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... defining point of care patient engagement to bedside smart ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... Sept, 21 OmniComm Systems, Inc. (OTC ... of eClinical solutions and services announced that it will ... at the Hilton Beach Resort in Fort Lauderdale, Florida ... presentations and speakers from participating Life Science organizations. The ...
... The Pittsburgh Life Sciences Greenhouse (PLSG), the ... and business growth programs to western Pennsylvania,s life ... nationally recognized Executives-in-Residence (EIR) has launched a new ... (Ib2C(TM)). Ib2C(TM) Founder and CEO, Stephen ...
Cached Medicine Technology:OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 2Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 4
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... MyWriters.com , an online source for ... for marketers to help them drive traffic to their ... Shane Michaels, prompting an investigative review. , “Anyone ... knows that content is king when it comes to ... even though content is extremely important, creating quality, original ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Boston, Mass. (PRWEB) August 22, 2014 ... Chain Drug Stores (NACDS) Total Store Expo - which ... Boston Globe published a pro-pharmacy op-ed in its online ... medical care, enlist pharmacists ” is co-authored by Steven ... and Michael Malloy, PharmD, dean of the MCPHS University ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase ... of drug use among teenagers. The treatment facility aims to ... work to minimize drug abuse. , America is currently seeing ... in history. According to the National Institute of Drug ... 12 or older—or 9.2 percent of the population—had used an ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... passed on a rare side effect of the smallpox vaccination he ... , The boy who is currently being treated at University of ... percent of his body. ,Eczema vaccinatum is an unusual ... receive the shot or their close contacts. , The ...
... journal Proceedings of the National Academy of Sciences. The report ... in// preventing tuberculosis, and scientists may do well to resurrect ... led by Dr. Roland Brosch of the Institut Pasteur ... vaccines used in immunization of 2 million children around ...
... the first in the state to perform a novel ... regeneration of the heart muscle after a// heart attack. ... in the country providing this new treatment modality as ... a privately funded cell-therapy company studying stem cells for ...
... gene variants in Hispanic women are linked to spontaneous preterm ... Washington University.// ,The research was presented at the ... 16. ,Preterm birth is a major cause of ... birth was suggested by racial disparity, a tendency to occur ...
... have developed a procedure that estimates the reproductive potential ... multiple births and to achieve a higher success rate ... fertilization procedures are performed each year in the United ... in IVF cycles, but only 34.3 percent resulted in ...
... part of the body, could be an indicator of common ... development of new treatment. ,Zinc had previously been ... brains of patients with Alzheimer's disease. It is also vital ... ,Zinc is particularly important for healthy skin and ...
Cached Medicine News:Health News:Toddler Infected With Rare Side Effect of Smallpox Vaccine 2Health News:TB Vaccines: Ring Out the New, Bring in the Old 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 3Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2
... M1 is an advanced desktop PC ... is a sophisticated 2 channel stimulation ... electrical stimulations, 2 sound stimulations and ... You can customize each stimulation independently. ...
... MagPro is the high performance magnetic stimulator for ... medical research. , ,MagPro is able to stimulate ... studies of the field/nerve interface can be done ... waveform and coil-current direction. , , , , ...
... The X-SIZER System is ... system for thrombus removal ... and saphenous vein grafts. ... steel cutter and,continuous evacuation. ...
... the perfect partner for growing your business ... scalable to meet your needs now and ... your Allura Xper FD20 system supports mixed-use ... to new technologies allows you to add ...
Medicine Products: